Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Quantitative contribution of efflux to multi-drug resistance of clinical Escherichia coli and Pseudomonas aeruginosa strains
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 4515716
Author(s) Cunrath, Olivier; Meinel, Dominik M.; Maturana, Pauline; Fanous, Joseph; Buyck, Julien M.; Saint Auguste, Pamela; Seth-Smith, Helena M. B.; Körner, Jonas; Dehio, Christoph; Trebosc, Vincent; Kemmer, Christian; Neher, Richard; Egli, Adrian; Bumann, Dirk
Author(s) at UniBasel Neher, Richard
Dehio, Christoph
Bumann, Dirk
Year 2019
Title Quantitative contribution of efflux to multi-drug resistance of clinical Escherichia coli and Pseudomonas aeruginosa strains
Journal EBioMedicine
Volume 41
Pages / Article-Number 479-487
Keywords Antibiotic resistance; Clinical strains; Efflux; Genetic engineering
Mesh terms Anti-Bacterial Agents, pharmacology; Bacteremia, microbiology, pathology; Bacterial Outer Membrane Proteins, genetics; Drug Resistance, Multiple, Bacterial, genetics; Escherichia coli, drug effects, genetics, isolation & purification; Escherichia coli Proteins, genetics; Gene Deletion; Humans; Membrane Transport Proteins, genetics; Microbial Sensitivity Tests; Pseudomonas aeruginosa, drug effects, genetics, isolation & purification; Whole Genome Sequencing
Abstract Efflux pumps mediate antimicrobial resistance in several WHO critical priority bacterial pathogens. However, most available data come from laboratory strains. The quantitative relevance of efflux in more relevant clinical isolates remains largely unknown.; We developed a versatile method for genetic engineering in multi-drug resistant (MDR) bacteria, and used this method to delete tolC and specific antibiotic-resistance genes in 18 representative MDR clinical E. coli isolates. We determined efflux activity and minimal inhibitory concentrations for a diverse set of clinically relevant antibiotics in these mutants. We also deleted oprM in MDR P. aeruginosa strains and determined the impact on antibiotic susceptibility.; tolC deletion abolished detectable efflux activity in 15 out of 18 tested E. coli strains, and modulated antibiotic susceptibility in many strains. However, all mutant strains retained MDR status, primarily because of other, antibiotic-specific resistance genes. Deletion of oprM altered antibiotic susceptibility in a fraction of clinical P. aeruginosa isolates.; Efflux modulates antibiotic resistance in clinical MDR isolates of E. coli and P. aeruginosa. However, when other antimicrobial-resistance mechanisms are present, inhibition of MDR efflux pumps alone is often not sufficient to restore full susceptibility even for antibiotics with a dramatic impact of efflux in laboratory strains. We propose that development of novel antibiotics should include target validation in clinical MDR isolates. FUND: Innovative Medicines Initiative of European Union and EFPIA, Schweizerischer Nationalfonds, Swiss National Research Program 72, EU Marie Skłodowska-Curie program. The funders played no role in design, data collection, data analysis, interpretation, writing of the report, and in the decision to submit the paper for publication.
Publisher Elsevier
ISSN/ISBN 2352-3964
edoc-URL https://edoc.unibas.ch/72440/
Full Text on edoc Available
Digital Object Identifier DOI 10.1016/j.ebiom.2019.02.061
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/30852163
ISI-Number 000464321900061
Document type (ISI) Journal Article
 
   

MCSS v5.8 PRO. 0.347 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
26/04/2024